The aspect of Pfizer's coronavirus vaccine that really stunned the company's scientists was the fact that vaccinated participants in the Phase 3 efficacy trial had protections against the pathogen by day 12, a time at which there was barely any antibody response, Stat News reports. "That was the biggest surprise," said Vidia Roopchand, Pfizer's principal scientist for viral vaccines.
Roopchand is still trying to figure exactly why that is — not that it's a bad thing — by poring over the data. One possibility is that other aspects of the immune system such as T-cells that Roopchand says have largely been neglected in immunology research may have played a significant role. It's possible, he suggested, that's more important to measure cellular immunity than look for a robust antibody response. "The 12-day protection data is telling us there's more to it," Roopchand told Stat. "This is a great time to learn."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
ACA opens 2025 enrollment, enters 2024 raceSpeed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
-
McDonald's sued over E. coli linked to burgerSpeed Read The outbreak has sickened at least 49 people in 10 states and left one dead
-
Long Covid: study shows damage to brain's 'control centre'The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
-
Israel, UN agree to Gaza pauses for polio vaccinationsSpeed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
-
FDA OKs new Covid vaccine, available soonSpeed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
-
Mpox: how dangerous is new health emergency?Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
-
WHO declares mpox a global health emergencySpeed Read An outbreak of the viral disease formerly known as monkeypox continues to spread in Africa
-
What is POTS and why is it more common now?The explainer The condition affecting young women
